Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

N. Fazio, R. Buzzoni, G. Delle Fave, M.E. Tesselaar, E. Wolin, E. Van Cutsem, P. Tomassetti, J. Strosberg, M. Voi, L. Bubuteishvili-Pacaud, A. Ridolfi, F. Herbst, J. Tomasek, S. Singh, M. Pavel, M.H. Kulke, J.W. Valle, J.C. Yao

Research output: Contribution to journalArticle

Abstract

In the phase III RADIANT-4 study, everolimus improved median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated (grade 1 or grade 2), non-functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.67; P
Original languageEnglish
Pages (from-to)174-181
Number of pages8
JournalCancer Science
Volume109
Issue number1
DOIs
Publication statusPublished - 2018

    Fingerprint

Keywords

  • everolimus
  • lung carcinoid
  • neuroendocrine tumors
  • progression-free survival
  • RADIANT-4
  • antineoplastic agent
  • adult
  • advanced cancer
  • aged
  • anemia
  • aphthous stomatitis
  • Article
  • asthenia
  • body weight loss
  • cancer chemotherapy
  • cancer regression
  • cancer survival
  • clinical outcome
  • cohort analysis
  • controlled study
  • coughing
  • decreased appetite
  • diarrhea
  • drug efficacy
  • drug safety
  • dysgeusia
  • dyspnea
  • exploratory research
  • fatigue
  • female
  • fever
  • glossitis
  • human
  • hyperglycemia
  • infection
  • lung cancer
  • major clinical study
  • male
  • median survival time
  • mouth ulcer
  • multicenter study (topic)
  • nausea
  • neuroendocrine tumor
  • peripheral edema
  • phase 3 clinical trial (topic)
  • pneumonia
  • post hoc analysis
  • priority journal
  • progression free survival
  • pruritus
  • randomized controlled trial (topic)
  • rash
  • side effect
  • stomatitis
  • treatment response
  • xerostomia
  • clinical trial
  • disease free survival
  • double blind procedure
  • lung tumor
  • middle aged
  • multicenter study
  • phase 3 clinical trial
  • prospective study
  • randomized controlled trial
  • treatment outcome
  • very elderly
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Disease-Free Survival
  • Double-Blind Method
  • Everolimus
  • Female
  • Humans
  • Lung Neoplasms
  • Male
  • Middle Aged
  • Neuroendocrine Tumors
  • Prospective Studies
  • Treatment Outcome

Cite this

Fazio, N., Buzzoni, R., Delle Fave, G., Tesselaar, M. E., Wolin, E., Van Cutsem, E., Tomassetti, P., Strosberg, J., Voi, M., Bubuteishvili-Pacaud, L., Ridolfi, A., Herbst, F., Tomasek, J., Singh, S., Pavel, M., Kulke, M. H., Valle, J. W., & Yao, J. C. (2018). Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Science, 109(1), 174-181. https://doi.org/10.1111/cas.13427